CMS Finalizes Reimbursement For Exact Sciences’ Colorectal Cancer Test

The agency affirmed a positive payment rate for Exact Science's Cologuard DNA stool test. The firm says it is beginning to implement its marketing plan targeting docs that more frequently prescribe fecal tests, and patients more broadly on social media.

CMS has finalized its positive payment policy for Exact Sciences Corp.’sCologuard DNA stool test, the firm announced Nov. 25.

The agency has agreed to reimburse the physician-prescribed take-home test used to detect colorectal cancer at the $502 per unit...

More from Archive

More from Medtech Insight

European Hospital Products Sourced Through ‘System That Rewards Exploitation,’ Watchdog Finds

 
• By 

While European sustainability directives CSDDD and CSRD are still in the process of adoption, environmental group Swedwatch claims the EU's procurement framework is devoid of accountability.

Novel Pathway For Combined Drug/IVD Trials Wins Backing Of EU Nations

 
• By 

Broad participation by EU member states in a new pilot to test a unified procedure for evaluating applications for combined drug and IVD studies shows they recognize its value, says Monique Al, vice-chair of the Clinical Trials Coordination Group.

EU Life Sciences Strategy Must Address ‘Regulatory Lasagna’

 

MedTech Europe is ready to become involved and shape Europe’s Life Sciences Strategy and help drive regulatory simplification from the top to make the EU “the world’s most attractive place for life sciences by 2030.”